FDA Commissioner Marty Makary defends Replimune drug approval decision
Martin Makary, commissioner of the Food and Drug Administration (FDA), throughout a information convention on the US Food and Drug Administration headquarters in Silver Spring, Maryland, US, on Tuesday, April 28, 2026.
Valerie Plesch | Bloomberg | Getty Images
US Food and Drug Administration Commissioner Marty Makary defended himself in a CNBC interview aired Tuesday after months of strain over current drug rejections.
The relentless warmth reached a brand new fever pitch this week with a report from Bloomberg News detailing “paranoia, turmoil and backlash” on the company underneath Makary’s tenure. An opinion piece from The Wall Street Journal requested if any official administration has created extra complications for President Donald Trump than Makary. The editorial particularly cited the FDA’s controversial rejection of a drug candidate for melanoma from Replimune.
“I think that article in The Wall Street Journal is the ninth article they’ve published in that opinion section, begging for Replimune’s approval,” Makary stated in an interview with CNBC’s David Faber. “I don’t work for Replimune, I work for the American people, and I stand by the scientists at the FDA.”
Makary stated three impartial groups have arrived on the identical conclusion, including that the FDA has not made “corrupt sweetheart deals.” Replimune representatives have stated the FDA has unfairly handled the corporate.
Makary stated he stands behind his evaluation groups and that FDA commissioners overruling company scientists has been a “disaster” each time it has occurred. I’ve cited examples just like the FDA’s approval of an Alzheimer’s illness drug known as Aduhelm and its clearance of a Covid-19 vaccine booster for younger, wholesome youngsters.
